Phase 1-2 Trial HCQ Plus TACE in Unresectable HCC

Abramson Cancer Center at Penn Medicine

Status and phase: Terminated; Phase 2; Phase 1

Conditions: Hepatocellular Carcinoma

Treatments: Drug: HCQ

Study type: Interventional

Funder types: Other

Identifiers

NCT02013778

UPCC 22213

Details and patient eligibility

About

Primary Phase I:To determine dose limiting toxicities and maximum tolerated dose (MTD) of the oral administration of hydroxychloroquine (HCQ) in conjunction with transarterial chemoembolization (TACE) in treating hepatocellular carcinoma (HCC). A conventional 3+3 design will be utilized. Primary Phase II: To evaluate the complete response rate in a cohort of patients treated at the MTD, A Simon's Optimal Two-stage design will be utilized.

Enrollment: 8 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patient capable of giving informed consent
• Patient diagnosed with hepatocellular carcinoma in both lobes of the liver by one of the following methods (Pathologically confirmed HCC by biopsy or HCC 2 cm with classic radiographic findings of arterial phase enhancement with venous phase washout and pseudocapsule formation on contrast enhanced MRI or CT or Lesion greater than 2 cm with probable imaging features of HCC and imaging findings of cirrhosis and/or portal hypertension or a serum alphafetoprotein (AFP) greater than 200 mg/mL.
• Patient not candidate for orthotopic liver transplantation at the Hospital of the University of Pennsylvania based on review of patient imaging and history at multidisciplinary Hepatic Tumor Conference at the Hospital of the University of Pennsylvania.
• Age 18 years old
• Albumin 2.4 g/dL; Total bilirubin 2 mg/dL; INR 1.5
• Creatinine 2.0 mg/dL, AST 121 IU/L; ALT 189 IU/L
• Child-Turcotte-Pugh Classification A or B
• Eastern Clinical Oncology Group performance status 0 or1.

Exclusion criteria

• Prior TACE
• Active GI hemorrhage within 2 weeks of study enrollment
• Ascites refractory to medical therapy
• Contraindication to receiving HCQ or TACE
• Unilobar HCC
• Contraindication to contrast enhanced MRI (i.e. unable to undergo follow-up imaging)
• Women who are pregnant
• Participation in another concurrent treatment protocol

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

8 participants in 1 patient group

TACE + HCQ

Experimental group

Description:

Subjects will receive HCQ plus standard of care TACE.

Treatment:

Drug: HCQ